Key Facts & Figures
- Group sales rise 4%1 to 45.5 billion Swiss francs due to oncology sales, clinical laboratories business
- Core EPS 10% higher at 13.62 Swiss francs
- Operating free cash flow rises 10% to 15.4 billion Swiss francs
- HER2-franchise strengthened by Perjeta launch, filing of T-DM1 in US and Europe
- Board proposes dividend increase of 8% to 7.35 Swiss francs, the 26th consecutive year of growth
- Outlook for 2013: sales to grow in line with previous year, core earnings per share targeted to grow ahead of sales. Roche expects to further increase dividend.
1) Unless otherwise stated, all growth rates are calculated using constant exchange rates (average full-year 2011), with the exception of changes to core operating profit margins.
Cancer medicines lead growth, HER2-franchise strengthened
Sales by the Pharmaceuticals Division rose 5%, with sales of cancer medicines increasing 9%. Sales of MabThera/Rituxan, Herceptin, and Avastin remained strong throughout the year. Solid uptake of Zelboraf in the United States and Western Europe also supported the oncology growth. Rheumatoid arthritis medicine Actemra/RoActemra and hepatitis treatment Pegasys further lifted the division’s performance in 2012.
Strong immunoassay business drives worldwide sales
Roche Diagnostics maintained its leadership in the global in vitro diagnostics market, with sales growth of 4% and a 20% overall market share. Professional Diagnostics was the main growth contributor, led by its immunoassay business (+15%), which helps diagnose a range of diseases through highly automated immunochemical blood testing. Tissue and Molecular Diagnostics’ sales were driven by the advanced staining business and by the blood screening business and HCV monitoring, respectively.